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Abstract 
This study was designed to investigate the
relationship between SIRTs 1 and 4 in periph-
eral blood leukocytes (PBLs) and human type 2
diabetes mellitus (T2DM). SIRTs 1 and 4 have
been confirmed to be associated with home-
ostasis of glucose/lipid metabolism, but their
roles  in  T2DM  are  still  poorly  understood.
Peripheral  blood  and  biochemical  data  were
collected from 52 healthy individuals (normal
control  group,  NC  group)  and  113  cases  of
T2DM patients. Immunocytochemical staining
was  used  to  detect  SIRT1  and  SIRT4  and
reverse transcription polymerase chain reac-
tion  (RT-PCR)  was  used  to  detect  SIRT1  or
SIRT4  mRNA  levels  in  PBLs.  Immuno  -
cytochemical  staining  showed  that  SIRT1  is
expressed in both nucleus and cytoplasm, and
SIRT4  in  the  cytoplasm  of  granulocytes  and
monocytes. No SIRT1 or SIRT4 was found in
lymphocytes. RT-PCR showed that SIRT1 and
SIRT4 mRNA levels in T2DM group were lower
than those in NC group (P<0.01). Correlation
analysis showed that there is a negative corre-
lation between SIRTs 1 and 4 and fasting plas-
ma  glucose  (FPG)  (P<0.05)  (r=-0.161  and  -
0.156), a positive correlation between SIRT4
mRNA levels and triglyceride (TG)/lipoprotein
a (LPa) levels (P<0.05), and a negative corre-
lation between SIRT4 mRNA levels and high
density  lipoprotein  cholesterol  (HDL)
(P<0.05). SIRTs 1 and 4 may have a role in the
pathogenesis of T2DM and their expression in
granulocytes  and  monocytes  may  indirectly
reflect the homeostasis of glucose/lipid metab-
olism in T2DM.
Introduction
With the improvement of living standards,
population aging, and the rise in obesity, the
incidence of diabetes is annually increasing
worldwide. Type 2 diabetes mellitus (T2DM) is
an  age-related  disease.  Multiple  risk  factors
associated with aging, including scarce physi-
cal activity and weight gain, together with the
increase  of  complications  following  multiple
drug application and coexistence with chronic
diseases,  may  lead  to  pancreatic  islet  β-cell
dysfunction, insulin resistance and impaired
glucose tolerance, and even lead to the occur-
rence of T2DM. Although the underlying mech-
anism  behind  aging  is  still  unclear,  current
research  has  shown  that  caloric  restriction
(CR) is the most effective measure to slow the
aging  process  and  delay  the  occurrence  of
many  age-related  diseases  and  even  extend
lives  of  lower  organisms  (yeast,  nematodes,
fruit  flies)  and  mammals.1 Several  studies
showed that CR plays an important role mainly
through the signaling pathways of silent infor-
mation  regulator  (Sir2).2 Sir2,  a  histone
deacetylase, has been shown to play a key role
in the CR-mediated slowing down of aging in
yeast and nematodes.3 Homologous genes of
Sir2 in mammals are named sirtuins (SIRTs),
and include SIRTs 1-7.4
Researches  have  shown  that  SIRT1  can
adjust the deacetylase activity of a variety of
transcription factors that control many meta-
bolic  and  endocrine  signals,  and  is  widely
involved in the regulation of mammalian cell
life span, insulin secretion, and glucose/lipid
metabolism;5 SIRT4  regulates  insulin  secre-
tion and affects glucose metabolism by inhibit-
ing GDH regulation.6 Since T2DM involves the
imbalance  of  glucose/lipid  metabolism,  and
SIRTs 1 and 4 play key roles in maintaining the
balance of glucose/lipid metabolism,7 it is like-
ly that the expression of SIRTs 1 and 4 may be
associated with T2DM.
T2DM  occurs  along  with  β-cell  aging,
insulin secretion reduction and blood glucose
increase. Current drug therapies focus, on one
hand,  on  promoting  β-cell  insulin  secretion
and, on the other hand, on increasing the sen-
sitivity of target organs to insulin, protecting
β-cell  function,  preventing  aging,  and  then
regulating glucose/lipid metabolism and pro-
longing  life.  Therefore  a  close  relationship
exists between the clinical characteristics of
T2DM and β-cell function, whose assessment
could represent a rapid and simple marker for
monitoring the disease course and severity, as
well as the effect of drug treatment. Studies
have found that SIRT1 is expressed in the liver,
brain, kidney, fat, muscle tissue, and relatively
and uniformly expressed in islet β-cells, but
not in pancreatic exocrine cells,8 while SIRT4
is expressed in the pancreatic islets.9 However,
it is still unclear whether SIRTs 1 and 4 are
expressed  in  peripheral  blood  leukocytes
(PBLs,  including  granulocytes,  monocytes,
lymphocytes),  and  if  a  relationship  exists
between  SIRTs  1  and  4  expressions  in  the
PBLs and energy metabolism. Evidence indi-
cates that in CR condition, mammals up-regu-
late SIRT1 and down-regulate SIRT4 within the
pancreas.10 At the early stage of T2DM, insulin
resistance occurs along with the damage of β-
cell, and decreased expression of SIRTs 1 and
4.7 Most of the above studies were performed
in animals, and no research on SIRT1 or SIRT4
expression in T2DM patients has been report-
ed. This study was designed to investigate the
relationship between SIRT1 and SIRT4 in PBLs
and  T2DM,  and  to  observe  whether  SIRTs
expression in PBLs reflects the homeostasis of
glucose/lipid metabolism and the function of
β-cell, which is of great significance for pre-
vention, detection and treatment of T2DM.
Materials and Methods
Research subjects
One hundred and thirteen T2DM patients
[57  males,  56  females,  aged  45-75  years
(62.01±8.67 years)], who were hospitalized in
the  First  Affiliated  Hospital  of  Shantou
University  Medical  College  from  March  to
October in 2010 were involved in this study; all
patients met the 1999 WHO diagnostic criteria
for diabetes. Fifty-two normal healthy individu-
als [32 males, 20 females, aged 45-75 years
(59.58 ±11.28 years)], who came to the First
Affiliated  Hospital  of  Shantou  University
Medical College for healthy physical examina-
tion  from  March  to  October  in  2010,  were
designed as the control group. Every patient
and control subject signed an informed con-
sent form. The study protocol was approved by
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the Independent Ethics Committee of the First
Affiliated  Hospital  of  Shantou  University
Medical College and was performed in accor-
dance with the Declaration of Helsinki. 
Methods
Peripheral blood and biochemical data were
collected from every patients and control sub-
jects. 
PBLs separation 
Fresh  anticoagulated  peripheral  blood  (3
mL) was collected from each subject, and after
being centrifuged for 5 min at 1000 rpm, the
supernatant  was  discarded,  then  added  6-10
times  volumes  of  red  blood  cell  (RBC)  lysis
solution (KHCO3 1.0 g, NH4Cl 8.3 g, EDTA-Na
0.037 g, add water to 1000 mL), mixed gently,
and allowed RBC lysis for 4-5 min. Then the
solution  was  centrifuged  for  5  min  at  1000
rpm, the supernatant was discarded again. The
cell population was washed twice with phos-
phate buffered saline (PBS). Total RNA was
extracted and used for RT-PCR using standard
methods.
Immunocytochemical staining 
Immunocytochemical  staining  was  per-
formed  on  peripheral  blood  smear  to  detect
SIRT1 and SIRT4 protein expression by using
anti-SIRT1 or SIRT4 antibodies (1:100, Santa
Cruz Biotechnology, Inc., Santa Cruz, CA, USA)
with an overnight incubation at 4°C. The sam-
ples  were  then  incubated  with  a  secondary
antibody at 1:200 dilution (biotinylated anti-
rabbit  or  anti-goat  IgG,  Jackson  Immuno -
Research Corporation, West Grove, PA, USA) at
room temperature for 1 h, then with avidin-
biotin-horseradish  peroxidase  complex
(Promega Corporation, Madison, WI, USA) at
room temperature for 30 min, and visualized
with  amine  nickel  sulfate-enhanced  3,3’-
diaminobenzidine  (DAB).  Cells  were  then
counterstained with hematoxylin-eosin stain-
ing (HE). The sample was observed under a
light  microscope,  and  positive  staining  was
shown by the development of brown particles.
PBS was used instead of the primary antibody
for negative control reactions.
Reverse transcription polymerase chain
reaction 
Reverse  transcription  polymerase  chain
reaction (RT-PCR) was used to detect the rela-
tive  expression  levels  of  SIRT1  and  SIRT4
mRNA in PBLs. Total RNA was isolated from
PBLs  using  the  RNA  simple  Total  RNA  Kit
(Tiangen, Beijing, China). First-strand cDNAs
were  generated  by  using  EasyScript  First-
Stand  cDNA  Synthesis  SuperMix  Kit
(TransGen  Biotech  Ltd.,  Andhra  Pradesh,
India).  Primer  sequences  (Genecore,
Shanghai, China) are shown in Table 1. After
cDNA synthesis, the PCR assays were carried
out  using  2×  EasyTaq  PCR  SuperMix  kit
(TransGen Biotech), for 35 cycles of denatur-
ing at 94°C for 30 s, annealing at 53°C for 30 s,
extension at 72°C for 1 min, and further 10
min at 72°C in the last cycle. PCR products
were  subjected  to  1.5%  agarose  gel  elec-
trophoresis and visualized with ethidium bro-
mide. Relative expression was quantified den-
sitometrically  using  the  Gel  Image  Ver.  3.74
System (Tianon, Shanghai, China). 
Statistical analysis 
Statistical  analysis  was  performed  with
SPSS15.0 Statistical software. All values were
expressed as the mean ± standard deviation.
The statistical analysis was done by unpaired
or paired t-test and comparisons were made by
the χ2- test. Linear correlation was used for
correlative  analysis;  differences  with  P<0.05
were considered as statistically significant. 
Results
Demographic and clinical charac-
teristics of the two groups
Body mass index (BMI), systolic blood pres-
sure  (SBP),  and  diastolic  blood  pressure
(DBP) in the T2DM group were significantly
higher than those in the NC group (P<0.01).
There was no significant difference in gender
composition between the T2DM group and NC
group (P>0.05) (Table 2).
Statistics results showed that fasting plas-
ma  glucose  (FPG),  triglyceride  (TG)  and
lipoprotein a (LPa) in T2DM group were signif-
icantly  higher  than  those  in  NC  group
(P<0.01) (Table 3; Figure 1). Total cholesterol
(TC), high density lipoprotein (HDL), and low
Original paper
Table 1. The primers used in polymerase chain reaction.
Genes Forward primer (5'–3') Reverse primer (5'–3')
SIRT1 GCAACATCTTATGATTGGCACA AAATACCATCCCTTGACCTGAA
SIRT4 ACCCTGAGAAGGTCAAAGAGTTAC TTCCCCACAATCCAAGCAC
18S rRNA TTGGTGGAGCGATTTGTCTG AATGGGGTTCAACGGGTTAC
Table 2. Comparison clinical data of the two groups. 
Group Sex BMI SBP  DBP 
(male/female) (kg/m2) (mmHg) (mmHg)
NC group 32/20 22.40±1.35 115.87±10.32 75.81±8.71
T2DM group 57/56 23.81±2.79# 140.24±25.07* 83.26±10.68*
BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; ; BMI, body mass index; SBP, systolic blood pres-
sure; DBP, diastolic blood pressure; NC, control group; *P＜0.01; #P＜0.05.
Table 3. Blood glucose and lipid data of the two groups. 
Group FPG TC TG HDL LDL LPa
(mmol/L) (mmol/L) (mmol/L) (mmol/L) (mmol/L) (mmol/L)
NC group 4.97±0.53 4.83±0.75 1.14±0.31 1.09±0.15 2.97±0.74 198.26±64.26
T2DM group 9.42±3.40* 4.88±1.49 1.85±1.01* 1.10±0.29 2.84±1.04 299.40±132.60*
FPG, fasting plasma glucose; TC, total cholesterol; TG, triglyceride; HDL, high density lipoprotein; LDL, low density lipoprotein; LPa,
lipoprotein a; NC, control group; *P＜0. 01; #P＜0.05.
Figure  1.  Comparison  of  fasting  plasma
glucose, triglyceride, and lipoprotein a in
the  two  groups;  *P＜0.01  comparison
between  the  NC  group  and  the  T2DM
group. 
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density lipoprotein (LDL) in both groups were
no significantly different (P>0.05) (Table 3).
Liver  (AST,  ALT,  GGT)  and  renal  function
(BUN, Cr, UA) tests revealed no differences
between the two groups (P>0.05). PBLs num-
ber in T2DM group (7.52±1.69)¥109/L was sig-
nificantly higher than that in the NC group
(6.58±1.47)¥109/L (P<0.01).
Immunocytochemical staining 
The brown reaction products in the nucle-
us/cell  membrane  or  cytoplasm  represent
SIRTs 1 and 4 protein expression location. The
results show that SIRT1 is expressed in the
nucleus  and  cytoplasm  of  granulocytes  and
monocytes, and SIRT4 is mainly expressed in
the cytoplasm of these cell types; on the con-
trary, the expression of SIRTs 1 and 4 was not
obvious in lymphocytes (Figure 2).
RT-PCR results 
SIRTs 1 and 4 mRNA levels in the T2DM
group are significantly lower than those in NC
group (P<0.01) (Figure 3).
Correlation analysis between SIRTs
1 and 4 and blood glucose/lipid 
Correlation analysis (Table 4) showed that
there is a negative correlation between SIRTs
1  and  4  and  fasting  plasma  glucose  levels
(FPG) (P<0.05) (r=-0.161 and -0.156), a posi-
tive correlation between SIRT4 mRNA levels
and triglyceride (TG) and lipoprotein a (LPa)
(P<0.05), and a negative correlation between
SIRT4 mRNA levels and high density lipopro-
tein cholesterol (HDL) (P<0.05).
Discussion
Clinical  characteristics  of  the  two  groups
show that BMI, SBP, DBP, FPG, TG and LPa in
the T2DM group were all higher than those in
the NC group. The result implies that multiple
risk factors associating with aging, including
decreased physical activity, weight gain, along
with the increase of blood pressure and blood
glucose/lipids, may lead to islet β-cell dysfunc-
tion, insulin resistance and impaired glucose
tolerance, and even lead to the occurrence of
T2DM. 
Previous studies showed that SIRT1 protein
is  expressed  in  liver,  brain,  kidney,  fat  and
muscle tissues.8 SIRT4 protein is expressed in
pancreatic islets,9 but the immunocytochemi-
cal staining of this study showed that SIRT1
and SIRT4 are not only expressed in the men-
tioned  tissues,  but  both  of  them  are  also
expressed in PBLs (granulocytes, monocytes).
Moreover, SIRT1 is expressed in the nucleus
and cytoplasm of granulocytes and monocytes,
consistent with another study that found that
SIRT1  is  mainly  located  in  the  nucleus,  but
also in the cytoplasm, and exhibits nuclear -
cytoplasm  shuttling.11 SIRT4  is  mainly
expressed in the cytoplasm of granulocytes and
monocytes.
Many studies have indicated that SIRTs 1
and 4 take part in both glucose homeostasis
and  energy  metabolism.12 RT-PCR  results  of
this study are also consistent with a previous
study  on  animals.7 Correlation  analysis
between SIRTs 1 and 4 vs. blood glucose/lipid
shows that there is a significant correlation
between SIRTs 1 and 4 and FPG, TG, LPa and
HDL. All these results confirmed that there is a
relevance between the expression of SIRTs 1
and  4  in  PBLs  and  T2DM  and  blood
glucose/lipids.
SIRTs 1 and 4 activity depends on intracellu-
lar NAD+/NADH ratio, and nicotinamide13 dur-
ing calorie restrict (CR) condition or fasting,14
which  have  shown  that  SIRTs  1  and  4  are
closely  related  to  the  regulation  of  energy
metabolism.  NAD+/NADH  ratio  increases  as
well as the SIRTs 1 and 4 expressions. The
NAD+/NADH ratio (or nicotinamide concentra-
tion) is likely to be a primary determinant of
regulation, and SIRTs 1 and 4 could be regulat-
ed by CR in a given cell, since the NAD+/NADH
ratio has the potential to equilibrate cellular
compartments by shuttle systems.15 The result
of this study showed that a high blood sugar
level  in  T2DM  patients  will  decrease  NAD+/
NADH  ratio,  with  a  subsequent  decrease  of
Original paper
Table  4.  Correlation  analysis  between
SIRT1/18S  RNA,  SIRT4/18S  RNA  and
blood glucose/lipid. 
SIRT1/18S RNA SIRT4/18S RNA
FPG (mmol/L) r=-0.161 r=-0.167
P=0.037 P=0.045
WBC (¥109/L) r=-0.135 r=-0.145
P=0.104 P=0.106
TC (mmol/L) r=0.114 r=0.090
P=0.157 P=0.291
TG (mmol/L) r=-0.036 r=-0.169
P=0.656 P=0.049
HDL (mmol/L) r=-0.006 r=0.182
P=0.938 P=0.032
LDL (mmol/L) r=0.098 r=0.092
P=0.250 P=0.308
LPa (mmol/L) r=-0.169 r=-0.235
P=0.111 P=0.028
FPG, fasting plasma glucose; WBC, white blood cell; TC, total
cholesterol;  TG,  triglyceride;  HDL,  high  density  lipoprotein;
LDL, low density lipoprotein; LPa, lipoprotein a.   
Figure 2. Immunocytochemical staining of SIRTs 1 and 4 in PBLs. Pink arrow, mono-
cytes; blue arrow, granulocyte; green arrow, lymphocytes. A, B, positive staining; C, neg-
ative control. Scale bar: 10 µm.
Figure 3. Agarose gel electrophoresis figure for RT-PCR products of SIRTs 1 and 4 and
comparison SIRT1/18S, SIRT4/18S data of the two groups; *P＜0.01; #P＜0.05，com-
parison between NC and T2DM groups.[page 58] [European Journal of Histochemistry 2011; 55:e10]
SIRTs 1 and 4 expressions.
SIRT1 has histone deacetylase activity, acts
as a multifunctional transcription factor, and is
closely related to life activities, broadly partici-
pates in metabolic pathways, regulates the bal-
ance of energy metabolism and maintains glu-
cose/lipid metabolism homeostasis in the body.
T2DM  is  a  disorder  of  glucose/lipid  metabo-
lism, suggesting there may be a close relation-
ship  between  SIRT1  and  T2DM.  Gluconeo  -
genesis glycogen is one of the main factors
acting in maintaining high blood sugar in fast-
ing  and  CR  diabetes.  In  the  liver,  phos-
phoenolpyruvate  carboxykinase  (PEPCK)  is
one  of  the  gluconeogenesis  rate-limiting
enzymes. The PGC1-αprotein is a key factor in
PEPCK  regulation;  at  the  same  time,  SIRT1
can interact with its substrate PGC1-α, induc-
ing deacetylation of multiple lysine sites there-
in. Then, PGC1-α interacts with the hepato-
cyte nuclear factor 24 (HNF24) after deacetyla-
tion, contributes to increasing of liver gluco-
neogenesis gene transcription, and decreasing
of glycolysis related genes, thus inhibiting gly-
colysis. Moreover, SIRT1 promotes gluconeoge-
nesis  glycogen  and  increases  the  output  of
glycogen.16 This study shows that there is a
correlation between the expression of SIRT1 in
PBLs and T2DM, blood glucose/lipids, in agree-
ment with previous studies. The above results
imply that SIRT1 expression in PBLs is related
to SIRT1 expression in liver cells and may par-
ticipate in regulating blood glucose as well. A
previous study found that, in the fasting or CR
cases,  SIRT1  expression  is  elevated  in  the
liver, pancreas, muscle, brain, and adipose tis-
sues of rodents.16 A previous study on animals
has shown that in high-sugar or high-fat rat
model  of  insulin  resistance,  the  pancreatic
SIRT1  expression  is  reduced.2 The  study  is
consistent  with  the  results  of  these  experi-
ments,  indicating  the  equivalence  of  SIRT1
expression in both islet β-cell and PBLs.
Unlike other SIRT family members, SIRT4
has no deacetylation activity. Instead, it has a
strong  ADP-ribosyltransferase  activity  and  is
able  to  transfer  the  adenosine  diphosphate
ribose residues (ADPR) of NAD+ to its protein
substrate.9 Moreover, it has been found that
SIRT4  can  regulate  insulin  secretion  by
inhibiting  the  glutamate  dehydrogenase
(GDH) activity.6 In SIRT4 knockout mice or in
CR,  GDH  is  activated  and  it  up-regulates
insulin  secretion  of  β-cell  under  the  amino
acid stimulation.10 Based on the above experi-
mental  studies,  it  has  been  assumed  that
SIRT4 in pancreatic β-cell may play an oppo-
site effect compared with CR;10 namely, in the
high-sugar  situation  the  SIRT4  level
increased. However, a previous study on ani-
mals has found that SIRT4 expression decreas-
es  in  the  rat  model  of  insulin  resistance.7
Consistent with this study, our findings show
that SIRT4 expression in T2DM group is sig-
nificantly  lower  than  that  in  NC  group.
Furthermore, a recent study observed a signif-
icant increase in gene expression of mitochon-
drial  and  fatty  acid  metabolism  enzymes  in
hepatocytes  with  reduced  SIRT4  levels  in
SIRT4 knocked-down mice. SIRT4 knockdown
increased SIRT1 mRNA and protein levels both
in vitro and in vivo as well. The study also
showed a significant increase in fatty acid oxi-
dation  (FAO)  in  SIRT4  knockdown  primary
hepatocytes compared with control in consis-
tent with the increased FAO gene expression,
which  effect  was  dependent  on  SIRT1,  and
observed  a  significant  increase  in  hepatic
mitochondrial  and  FAO  gene  expression,  in
agreement with the findings in primary hepa-
tocytes.  The  study  demonstrated  that  SIRT4
inhibition increases fat oxidative capacity in
liver  and  mitochondrial  function  in  muscle,
which might provide therapeutic benefits for
diseases associated with ectopic lipid storage
such as T2DM.17 Therefore, SIRT4 is likely to
be associated with T2DM and SIRT4 absence is
likely to accelerate the development of T2DM.18
However, further exploration and research are
needed as on to identify the possible likeliness
of SIRT4 expression in PBLs and islet β-cell,
and whether the detection of SIRT4 in PBLs
can reflect the function of pancreatic β-cell.
T2DM is also considered to be a systemic
chronic inflammatory disease, as it not only
exhibits a decline in β-cell function, but also
reduces  insulin  secretion  by  β-cell  and
increases blood sugar. At the same time, the
presence of leukocytes, which are inflammato-
ry cells, in T2DM reveal a discrepancy of glu-
cose metabolism in PBLs; thus, the PBLs func-
tion declines, affecting SIRTs 1 and 4 expres-
sion.  Therefore,  the  consistency  of  SIRT1
expression in islet β-cell and PBLs also shows
a correspondence of the two. 
This study shows that there is a significant
increase in PBLs in the T2DM group compared
with the NC group, which indicates that the
proliferation,  senescence  and  apoptosis  of
PBLs, as well as the inflammatory cells, are
likely to be associated with T2DM, a systemic
chronic inflammatory disease. SIRTs 1 and 4
expression in PBLs is also likely to be affected
by  the  proliferation,  aging  and  apoptosis  of
PBLs, and then SIRTs 1 and 4 would participate
to  the  development  of  T2DM,  although  this
needs  further  studies  to  be  confirmed.  The
function of pancreatic β-cell can not be detect-
ed directly in clinical situations; however, fur-
ther research should be performed to prove if it
can be indirectly identified by the combined
detection of SIRTs 1 and 4 in PBLs. Meanwhile,
there are significant differences in the expres-
sion of SIRTs 1 and 4 between T2DM group and
NC group, and this also suggests the relevance
between SIRTs 1 and 4 and T2DM.
In summary, our study suggests that SIRTs 1
and 4 may have a role in the pathogenesis of
T2DM, and that their expression in peripheral
granulocytes and monocytes may provide indi-
rect indication of the altered homeostasis of
glucose/lipid metabolism in T2DM.
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